Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1061

1.

Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences.

Wallach JD, Egilman AC, Gopal AD, Swami N, Krumholz HM, Ross JS.

Res Integr Peer Rev. 2018 Jan 5;3:1. doi: 10.1186/s41073-017-0045-8. eCollection 2018.

2.

Laboratory evidence of dynamo amplification of magnetic fields in a turbulent plasma.

Tzeferacos P, Rigby A, Bott AFA, Bell AR, Bingham R, Casner A, Cattaneo F, Churazov EM, Emig J, Fiuza F, Forest CB, Foster J, Graziani C, Katz J, Koenig M, Li CK, Meinecke J, Petrasso R, Park HS, Remington BA, Ross JS, Ryu D, Ryutov D, White TG, Reville B, Miniati F, Schekochihin AA, Lamb DQ, Froula DH, Gregori G.

Nat Commun. 2018 Feb 9;9(1):591. doi: 10.1038/s41467-018-02953-2.

3.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R.

PLoS Comput Biol. 2018 Feb 7;14(2):e1005965. doi: 10.1371/journal.pcbi.1005965. [Epub ahead of print]

4.

Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis.

Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P.

Clin Pharmacol Ther. 2018 Jan 29. doi: 10.1002/cpt.1038. [Epub ahead of print]

PMID:
29377075
5.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Jan 26:JCO2017762294. doi: 10.1200/JCO.2017.76.2294. [Epub ahead of print]

PMID:
29373100
6.

Bringing Vioxx back to market.

Ross JS, Krumholz HM.

BMJ. 2018 Jan 25;360:k242. doi: 10.1136/bmj.k242. No abstract available.

PMID:
29371221
7.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus.

Schrock AB, Pavlick DC, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordonii R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe CE, Braiteh F, Ali SM, Miller V.

Clin Cancer Res. 2018 Jan 23. pii: clincanres.3103.2017. doi: 10.1158/1078-0432.CCR-17-3103. [Epub ahead of print]

PMID:
29363525
8.

Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals: Epidemiology and Recent Trends.

Charalel RA, Durack JC, Mao J, Ross JS, Meltzer AJ, Sedrakyan A.

Med Care. 2018 Mar;56(3):260-265. doi: 10.1097/MLR.0000000000000867.

PMID:
29356721
9.

Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.

Egilman AC, Wallach JD, Ross JS, Dhruva SS.

JAMA Intern Med. 2018 Jan 16. doi: 10.1001/jamainternmed.2017.8016. [Epub ahead of print] No abstract available.

PMID:
29340562
10.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM.

Cancer. 2018 Jan 16. doi: 10.1002/cncr.31125. [Epub ahead of print]

PMID:
29338072
11.

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.

Clin Breast Cancer. 2017 Dec 21. pii: S1526-8209(17)30680-8. doi: 10.1016/j.clbc.2017.12.010. [Epub ahead of print] No abstract available.

PMID:
29325860
12.

Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes.

Lindenauer PK, Strait KM, Grady JN, Ngo CK, Parisi ML, Metersky M, Ross JS, Bernheim SM, Dorsey K.

Ann Am Thorac Soc. 2018 Jan 3. doi: 10.1513/AnnalsATS.201709-728OC. [Epub ahead of print]

PMID:
29298090
13.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.

Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley W.

J Thorac Oncol. 2017 Dec 27. pii: S1556-0864(17)33112-X. doi: 10.1016/j.jtho.2017.12.009. [Epub ahead of print]

PMID:
29288764
14.

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.

Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P.

BMJ Open. 2017 Dec 21;7(12):e018587. doi: 10.1136/bmjopen-2017-018587.

15.

Defining Multiple Chronic Conditions for Quality Measurement.

Drye EE, Altaf FK, Lipska KJ, Spatz ES, Montague JA, Bao H, Parzynski CS, Ross JS, Bernheim SM, Krumholz HM, Lin Z.

Med Care. 2018 Feb;56(2):193-201. doi: 10.1097/MLR.0000000000000853.

PMID:
29271820
16.

Data Sharing and Cardiology: Platforms and Possibilities.

Dey P, Ross JS, Ritchie JD, Desai NR, Bhavnani SP, Krumholz HM.

J Am Coll Cardiol. 2017 Dec 19;70(24):3018-3025. doi: 10.1016/j.jacc.2017.10.037. Review.

PMID:
29241491
17.

New and incremental FDA black box warnings from 2008 to 2015.

Solotke MT, Dhruva SS, Downing NS, Shah ND, Ross JS.

Expert Opin Drug Saf. 2018 Feb;17(2):117-123. doi: 10.1080/14740338.2018.1415323. Epub 2017 Dec 17.

PMID:
29215916
18.

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.

Miller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM.

BMJ Open. 2017 Dec 5;7(12):e017917. doi: 10.1136/bmjopen-2017-017917.

19.

Collaborative Multi-institutional Experience in Comparing PD-L1 Immunohistochemistry Assays: Concordance of SP142 and 22C3 Immunoreactivity.

Abdul Karim L, Kallakury BVS, Chahine JJ, Sheehan CE, Ross JS.

Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e22. doi: 10.1097/PAI.0000000000000609. No abstract available.

PMID:
29189261
20.

Physician Denial of Inappropriate Patient Requests-What If I Say No??

Ross JS.

JAMA Intern Med. 2018 Jan 1;178(1):92. doi: 10.1001/jamainternmed.2017.7367. No abstract available.

PMID:
29181540
21.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM.

Pigment Cell Melanoma Res. 2017 Nov 24. doi: 10.1111/pcmr.12674. [Epub ahead of print]

PMID:
29171936
22.

Reply to Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein-Barr virus in situ assays.

Ali SM, Ross JS, Wang K.

Cancer. 2018 Jan 15;124(2):435-436. doi: 10.1002/cncr.31132. Epub 2017 Nov 22. No abstract available.

PMID:
29165787
23.

Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.

Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S.

J Natl Cancer Inst. 2017 Nov 15. doi: 10.1093/jnci/djx213. [Epub ahead of print]

PMID:
29155997
24.

High Costs of FDA Approval for Formerly Unapproved Marketed Drugs.

Hakim A, Gupta R, Ross JS.

JAMA. 2017 Dec 12;318(22):2181-2182. doi: 10.1001/jama.2017.16481. No abstract available.

PMID:
29131905
25.

Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.

Kim J, Ross JS, Kapczynski A.

JAMA. 2018 Jan 2;319(1):21-22. doi: 10.1001/jama.2017.16477. No abstract available.

PMID:
29117365
26.

Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.

Lin DI, Chudnovsky Y, Duggan B, Zajchowski D, Greenbowe J, Ross JS, Gay LM, Ali SM, Elvin JA.

Gynecol Oncol. 2017 Dec;147(3):626-633. doi: 10.1016/j.ygyno.2017.09.031. Epub 2017 Nov 6.

PMID:
29102090
27.

Two-photon absorption measurements of deep UV transmissible materials at 213  nm.

Patankar S, Yang ST, Moody JD, Swadling GF, Erlandson AC, Bayramian AJ, Barker D, Datte P, Acree RL, Pepmeier B, Madden RE, Borden MR, Ross JS.

Appl Opt. 2017 Oct 20;56(30):8309-8312. doi: 10.1364/AO.56.008309.

PMID:
29091606
28.

Association between FDA black box warnings and Medicare formulary coverage changes.

Dhruva SS, Karaca-Mandic P, Shah ND, Shaw DL, Ross JS.

Am J Manag Care. 2017 Sep 1;23(9):e310-e315.

29.

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM.

Oncologist. 2017 Dec;22(12):1444-1450. doi: 10.1634/theoncologist.2016-0488. Epub 2017 Oct 27.

PMID:
29079636
30.

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.

Lee H, El Jabbour T, Ainechi S, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon SH, Ali SM, Schrock A, Fabrizio D, Frampton G, Nazeer T, Miller VA, Stephens PJ, Ross JS.

Hum Pathol. 2017 Dec;70:84-91. doi: 10.1016/j.humpath.2017.10.007. Epub 2017 Oct 24.

PMID:
29079173
31.

Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015.

Samuels EA, Ross JS, Dhruva SS.

Ann Intern Med. 2017 Dec 19;167(12):895-896. doi: 10.7326/M17-1823. Epub 2017 Oct 10. No abstract available.

PMID:
29052693
32.

Research, regulatory, and clinical decision-making: the importance of scientific integrity.

Wallach JD, Gonsalves GS, Ross JS.

J Clin Epidemiol. 2018 Jan;93:88-93. doi: 10.1016/j.jclinepi.2017.08.021. Epub 2017 Oct 16. No abstract available.

PMID:
29042327
33.

Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply.

Downing NS, Shah ND, Ross JS.

JAMA. 2017 Sep 19;318(11):1067-1068. doi: 10.1001/jama.2017.11517. No abstract available.

PMID:
28975302
34.

Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System.

Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ.

Clin Genitourin Cancer. 2017 Sep 7. pii: S1558-7673(17)30276-8. doi: 10.1016/j.clgc.2017.09.001. [Epub ahead of print]

PMID:
28974397
35.

Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling.

Dharmarajan K, McNamara RL, Wang Y, Masoudi FA, Ross JS, Spatz EE, Desai NR, de Lemos JA, Fonarow GC, Heidenreich PA, Bhatt DL, Bernheim SM, Slattery LE, Khan YM, Curtis JP.

Ann Intern Med. 2017 Oct 17;167(8):555-564. doi: 10.7326/M16-2871. Epub 2017 Sep 26.

PMID:
28973634
36.

Challenges to Biosimilar Substitution-Reply.

Hakim A, Ross JS.

JAMA. 2017 Sep 26;318(12):1186-1187. doi: 10.1001/jama.2017.11937. No abstract available.

PMID:
28973611
37.

Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use.

Jeffery MM, Hooten WM, Hess EP, Meara ER, Ross JS, Henk HJ, Borgundvaag B, Shah ND, Bellolio MF.

Ann Emerg Med. 2018 Mar;71(3):326-336.e19. doi: 10.1016/j.annemergmed.2017.08.042. Epub 2017 Sep 26.

38.

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.

Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, Somerset H, Johnson JM, Russell J, Ali S, Schrock AB, Fabrizio D, Frampton G, Miller V, Stephens PJ, Elvin JA, Bowles DW.

Ann Oncol. 2017 Oct 1;28(10):2539-2546. doi: 10.1093/annonc/mdx399.

PMID:
28961851
39.

Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection.

Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA.

J Allergy Clin Immunol Pract. 2017 Sep 22. pii: S2213-2198(17)30559-7. doi: 10.1016/j.jaip.2017.07.034. [Epub ahead of print]

PMID:
28958746
40.

Merits of Data Sharing: The Digitalis Investigation Group Trial.

Angraal S, Ross JS, Dhruva SS, Desai NR, Welsh JW, Krumholz HM.

J Am Coll Cardiol. 2017 Oct 3;70(14):1825-1827. doi: 10.1016/j.jacc.2017.07.786. No abstract available.

PMID:
28958337
41.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

PMID:
28945887
42.

The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.

Gupta R, Dhruva SS, Fox ER, Ross JS.

J Manag Care Spec Pharm. 2017 Oct;23(10):1066-1076. doi: 10.18553/jmcp.2017.23.10.1066.

43.

Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.

Zeitoun JD, Baron G, Vivot A, Atal I, Downing NS, Ross JS, Ravaud P.

Int J Cancer. 2018 Jan 15;142(2):414-423. doi: 10.1002/ijc.31061. Epub 2017 Oct 12.

PMID:
28929484
44.

Identifying Sociodemographic Characteristics Associated With Burden Among Caregivers of the Urban Homebound: The Importance of Racial and Relationship Differences.

Wajnberg A, Soones TN, Smith KL, Russell D, Ross JS, Federman A.

Gerontol Geriatr Med. 2016 Sep 8;2:2333721416667878. doi: 10.1177/2333721416667878. eCollection 2016 Jan-Dec.

45.

Quality of Care in the United States Territories, 1999-2012.

Nuti SV, Wang Y, Masoudi FA, Nunez-Smith M, Normand ST, Murugiah K, Rodríguez-Vilá O, Ross JS, Krumholz HM.

Med Care. 2017 Oct;55(10):886-892. doi: 10.1097/MLR.0000000000000797.

PMID:
28906314
46.

Hospital-Readmission Risk - Isolating Hospital Effects from Patient Effects.

Krumholz HM, Wang K, Lin Z, Dharmarajan K, Horwitz LI, Ross JS, Drye EE, Bernheim SM, Normand ST.

N Engl J Med. 2017 Sep 14;377(11):1055-1064. doi: 10.1056/NEJMsa1702321.

PMID:
28902587
47.

Can machine learning complement traditional medical device surveillance? A case study of dual-chamber implantable cardioverter-defibrillators.

Ross JS, Bates J, Parzynski CS, Akar JG, Curtis JP, Desai NR, Freeman JV, Gamble GM, Kuntz R, Li SX, Marinac-Dabic D, Masoudi FA, Normand ST, Ranasinghe I, Shaw RE, Krumholz HM.

Med Devices (Auckl). 2017 Aug 16;10:165-188. doi: 10.2147/MDER.S138158. eCollection 2017.

48.

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.

Oztan A, Fischer S, Schrock AB, Erlich RL, Lovly CM, Stephens PJ, Ross JS, Miller V, Ali SM, Ou SI, Raez LE.

Lung Cancer. 2017 Sep;111:84-87. doi: 10.1016/j.lungcan.2017.07.002. Epub 2017 Jul 8.

PMID:
28838405
49.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993.

50.

US Food and Drug Administration Clearance of Moderate-Risk Otolaryngologic Devices via the 510(k) Process, 1997-2016.

Rathi VK, Gadkaree SK, Ross JS, Kozin ED, Sethi RK, Naunheim MR, Puram SV, Gray ST.

Otolaryngol Head Neck Surg. 2017 Oct;157(4):608-617. doi: 10.1177/0194599817721689. Epub 2017 Aug 8.

PMID:
28786317

Supplemental Content

Support Center